Aggressive B-cell lymphomas with translocations involving BCL6 and MYC have distinct clinical-pathologic characteristics

American Journal of Clinical Pathology

Volumn 142, Issue 3, 2014, Pages 339-346

  Turakhia, Samir K ^a   Hill, Brian T ^b   Dufresne, Scott D ^c   Nakashima, Megan O ^a   Cotta, Claudiu V ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b TAUSSIG CANCER INSTITUTE   (United States)

^c Dahl Chase Pathology Associates   (United States)

Author keywords

BCL6; Burkitt; Double hit; FISH; Immunohistochemistry; Large B cell; Lymphoma; MYC

Indexed keywords

MYC PROTEIN; PROTEIN BCL 6; BCL6 PROTEIN, HUMAN; DNA BINDING PROTEIN; MYC PROTEIN, HUMAN;

ARTICLE; B CELL LYMPHOMA; B LYMPHOCYTE; BURKITT LYMPHOMA; CERVICAL LYMPH NODE; CLINICAL FEATURE; ELECTRONIC MEDICAL RECORD; FLUORESCENCE IN SITU HYBRIDIZATION; GENE TRANSLOCATION; GERMINAL CENTER; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; LARGE CELL LYMPHOMA; LIQUID CHROMATOGRAPHY; MEDICAL EDUCATION; NASOPHARYNX; PARAAORTIC LYMPH NODE; AGED; BCL6; BURKITT; DOUBLE HIT; FEMALE; FISH; GENETICS; HUMAN; LARGE B CELL; LYMPHOMA; MIDDLE AGED; MYC; PATHOLOGY;

BCL6; BURKITT; DOUBLE HIT; FISH; IMMUNOHISTOCHEMISTRY; LARGE B CELL; LYMPHOMA; MYC;

AGED; BURKITT LYMPHOMA; DNA-BINDING PROTEINS; FEMALE; HUMANS; IMMUNOPHENOTYPING; LYMPHOMA, B-CELL; MIDDLE AGED; PROTO-ONCOGENE PROTEINS C-MYC; TRANSLOCATION, GENETIC;

EID: 84907173853     PISSN: 00029173     EISSN: 19437722     Source Type: Journal    
DOI: 10.1309/AJCPBWVHTF7RRSA4     Document Type: Article

References (20)

1. Kluin PM, Harris NL, Stein H, et al. B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma. In: Swerdlow SH, Campo E, Harris NL, et al. World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon, France: IARC; 2008:265-266.
2. Dalla-Favera R, Bregni M, Erikson J, et al. Human c-myc onc gene is located on the region of chromosome 8 that is translocated in Burkitt lymphoma cells. Proc Natl Acad Sci U S A. 1982;79:7824-7827.
3. Taub R, Kirsch I, Morton C, e t al. Translocation of the c-myc gene into the immunoglobulin heavy chain locus in human Burkitt lymphoma and murine plasmacytoma cells. Proc Natl Acad Sci U S A. 1982;79:7837-7841.
4. Kramer MH, Hermans J, Wijburg E, et al. Clinical relevance of BCL2, BCL6, and MYC rearrangements in diffuse large B-cell lymphoma. Blood. 1998;92:3152-3162.
5. Horn H, Ziepert M, Becher C, et al. MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma. Blood. 2013;121:2253-2263.
6. Hummel M, Bentink S, Berger H, et al. A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling. N Engl J Med. 2006;354:2419-2430.
7. Dave SS, Fu K, Wright GW, et al. Molecular diagnosis of Burkitt's lymphoma. N Engl J Med. 2006;354:2431-2442.
8. Lai JL, Fenaux P, Zandecki M, et al. Cytogenetic studies in 30 patients with Burkitt's lymphoma or L3 acute lymphoblastic leukemia with special reference to additional chromosome abnormalit ies. Ann Genet. 1989;32:26-32.
9. Tibiletti MG, Martin V, Bernasconi B, et al. BCL2, BCL6, MYC, MALT 1, and BCL10 rearrangements in nodal diffuse large B-cell lymphomas: a multicenter evaluation of a new set of fluorescent in situ hybridization probes and correlation with clinical outcome. Hum Pathol. 2009;40:645-652.
10. Kanungo A, Medeiros LJ, Abruzzo LV, et al. Lymphoid neoplasms asso ciated with concurrent t(14;18) and 8q24/c-MYC translocation generally have a poor prognosis. Mod Pathol. 2006;19:25-33.
11. Aukema SM, Siebert R, Schuuring E, et al. Double-hit B-cell Lymphomas. Blood. 2011;117:2319-2331.
12. Iqbal J, Greiner TC, Patel K, et al. Distinctive patterns of BCL6 molecular alterations and their functional consequences in different subgroups of diffuse large B-cell lymphoma. Leukemia. 2007;21:2 332-2343.
13. Johnson NA,Savage KJ,Ludkovski O,et al. Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival Blood. 2009, 114, 2273-2279.
14. Pillai RK, Sathanoori M, Van Oss SB, et al. Double-hit B-cell lymphomas with BCL6 and MYC translocations are aggressive, frequently extranodal lymphomas distinct from BCL2 double-hit B-cell lymphomas. Am J Surg Patho l. 2013;37:323-332.
15. Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103:275-282.
16. Le Gouill S, Talmant P, Touzeau C, et al. The clinical presentation and prognosis of diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC rearrangement. Haematologica. 2007;92:1335-1342.
17. Dang CV. MYC on the path to cancer. Cell. 2012;149:22-35.
18. Ott G, Rosenwald A, Campo E. Understanding MYC-driven aggressive B-cell lymphomas: pathogenesis and classification. Hematology Am Soc Hematol Educ Program. 2013;2013:575-583.
19. Okita K, Ichisaka T, Yamanaka S. Generation of germline-competent induced pluripotent stem cells. Nature. 2007;448:313-317.
20. Bunting KL, Melnick AM. New effector functions and regulatory mechanisms of BCL6 in normal and malignant lymphocytes. Curr Opin Immunol. 2013;25:339-346.